HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER
申请人:Array Biopharma, Inc.
公开号:EP1989211A2
公开(公告)日:2008-11-12
US8003662B2
申请人:——
公开号:US8003662B2
公开(公告)日:2011-08-23
[EN] HETEROBICYCLIC THIOPHENE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES DE THIOPHÈNE ET LEURS MÉTHODES D'UTILISATION
申请人:ARRAY BIOPHARMA INC
公开号:WO2008063202A2
公开(公告)日:2008-05-29
[EN] Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. [FR] L'invention porte sur des composés de formule (I) et leurs sels pharmaceutiquement acceptables inhibant le récepteur des tyrosine kinases et traitant des troubles médiés par elles, et sur des méthodes les utilisant permettant d'effectuer des diagnostics in vitro, in situ et in vivo, et de prévenir ou traiter de tels troubles dans des cellules mammifères ou les états pathologiques associées.
Heterobicyclic thiophene compounds and methods of use
申请人:Blake F. James
公开号:US20070197537A1
公开(公告)日:2007-08-23
Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.